Literature DB >> 10551568

Perflubron emulsion delays blood transfusions in orthopedic surgery. European Perflubron Emulsion Study Group.

D R Spahn1, R van Brempt, G Theilmeier, J P Reibold, M Welte, H Heinzerling, K M Birck, P E Keipert, K Messmer, H Heinzerling, K M Birck, P E Keipert, K Messmer.   

Abstract

BACKGROUND: Fluorocarbon emulsions have been proposed as temporary artificial oxygen carriers. The aim of the present study is to compare the effectiveness of perflubron emulsion with the effectiveness of autologous blood or colloid infusion for reversal of physiologic transfusion triggers.
METHODS: A multinational, multicenter, randomized, controlled, single-blind, parallel group study was performed in 147 orthopedic patients. Patients underwent acute normovolemic hemodilution with colloid to a target hemoglobin of 9 g/dl with an inspiratory oxygen fraction (FIO2) of 0.40. Patients were then randomized into one of four treatment groups after having reached any of the protocol-defined transfusion triggers including tachycardia (heart rate > 125% of posthemodilution rate or > 110 bpm), hypotension (mean arterial pressure < 75% of posthemodilution level or < or = 60 mmHg), elevated cardiac output (> 150% of posthemodilution level) or decreased mixed venous oxygen partial pressure (PVO2; < 38 mmHg). Treatments in the four groups were 450 ml autologous blood harvested during acute normovolemic hemodilution given at FO2 = 0.40; 450 ml colloid at FIO2 = 1.0; 0.9 g/kg perflubron emulsion with colloid (total = 450 ml) at FIO2 = 1.0; and 1.8 g/kg perflubron emulsion with colloid (total = 450 ml) at FIO2 = 1.0. The primary endpoint was duration of transfusion-trigger reversal. A secondary end-point was percentage of transfusion-trigger reversal.
RESULTS: Perflubron emulsion was well tolerated with no serious adverse event attributed to drug treatment. Duration of reversal was longest in the 1.8 g/kg perflubron group (median, 80 min; 95% confidence interval, 60-100 min; P = 0.014 vs. autologous blood, P < 0.001 vs. colloid) followed by the 0.9 g/kg perflubron group (median, 59 min; 95% confidence interval, 40-90 min), the autologous blood group (median, 55 min; 95% confidence interval, 30-70 min) and the colloid group (median, 30 min; 95% confidence interval, 27-60 min). Percentage of reversal was also highest in the 1.8 g/kg perflubron group (97%; P < 0.001 vs. autologous blood; P = 0.014 vs. colloid), followed by 0.9 g/kg perflubron (82%), colloid (76%), and autologous blood (60%).
CONCLUSIONS: Perflubron emulsion (1.8 g/kg) combined with 100% oxygen ventilation is more effective than autologous blood or colloid infusion in reversing physiologic transfusion triggers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10551568     DOI: 10.1097/00000542-199911000-00009

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  16 in total

Review 1.  Volume replacement and microhemodynamic changes in polytrauma.

Authors:  Brigitte Vollmar; Michael D Menger
Journal:  Langenbecks Arch Surg       Date:  2004-04-28       Impact factor: 3.445

2.  Encapsulation and release of Amphotericin B from an ABC triblock fluorous copolymer.

Authors:  Jun-Pil Jee; Aaron McCoy; Sandro Mecozzi
Journal:  Pharm Res       Date:  2011-07-08       Impact factor: 4.200

Review 3.  [Perioperative management of Jehovah's Witness patients. Special consideration of religiously motivated refusal of allogeneic blood transfusion].

Authors:  O Habler; B Voss
Journal:  Anaesthesist       Date:  2010-04       Impact factor: 1.041

Review 4.  Bio-inspired nanomedicine strategies for artificial blood components.

Authors:  Anirban Sen Gupta
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-03-15

Review 5.  Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids.

Authors:  Pedro Cabrales; Marcos Intaglietta
Journal:  ASAIO J       Date:  2013 Jul-Aug       Impact factor: 2.872

6.  Delaying blood transfusion in experimental acute anemia with a perfluorocarbon emulsion.

Authors:  Pedro Cabrales; Juan Carlos Briceño
Journal:  Anesthesiology       Date:  2011-04       Impact factor: 7.892

Review 7.  [Artificial oxygen carriers as an alternative to red blood cell transfusion].

Authors:  O Habler; A Pape; J Meier; B Zwissler
Journal:  Anaesthesist       Date:  2005-08       Impact factor: 1.041

Review 8.  [Indications for blood transfusion during orthopedic surgery].

Authors:  O Habler; J Meier; A Pape; B Zwissler
Journal:  Orthopade       Date:  2004-07       Impact factor: 1.087

9.  Hemorheological implications of perfluorocarbon based oxygen carrier interaction with colloid plasma expanders and blood.

Authors:  Diana M Vásquez; Daniel Ortiz; Oscar A Alvarez; Juan C Briceño; Pedro Cabrales
Journal:  Biotechnol Prog       Date:  2013-04-18

Review 10.  Alternatives to blood in the 21st century.

Authors:  Stephen M Cohn
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.